Medtronic Receives European Nod For Glucose Monitoring System
Zacks Investment Research | Sep 19, 2019 08:41AM ET
Medtronic plc (NYSE:MDT) announced that it received CE Mark approval for its advanced continuous glucose monitoring (CGM) system — the Envision Pro CGM — in Europe. Following the regulatory nod, the device will be commercially available in Europe and the Middle East later this year, subject to fulfillment of local regulatory requirements.
The advancement in the technology will enable medical professionals and patients with either type 1 or type 2 diabetes to monitor accurate glucose levels and trends over time to opt for more informed therapy plans.
Medtronic, the first company to have a physician-approved CGM system, believes that the launch of Envision Pro is a turning point as the system is its first disposable and zero calibration CGM.
The company expects to improve its presence in the European market through this recognition.
For investors’ note, CGM is used to measure glucose levels every five minutes through a tiny sensor inserted below the skin, typically in the abdomen or upper arm.
Envision Pro CGM
Envision Pro CGM records glucose data through the Envision recorder and produces up to five diagnostic reports, which can be reviewed by physicians. With these, healthcare providers can simplify therapy adjustments and suggest lifestyle change advises to patients to reduce excursions and associated risks of complications.
How is it an Improved Version?
Per the experienced medical fraternity, the earlier versions of CGM, using fingersticks and A1C, only reflected the variations of sugar levels throughout the day. However, with the technological advancement made with Envision Pro CGM, doctors can see a report about the percent of time patients are in the ideal target glucose range and when they are beyond the limits to make more informed treatment decisions.
Another advantage is that the sensor and recorder are fully disposable and there is no need to return them to physicians. Additionally, the recorder communicates with the patient’s smartphone wirelessly, which healthcare provider can obtain effortlessly, thus allowing remote monitoring of reports without in-office visits.
Given the huge potential for offering treatments to diabetic patients, the approval and subsequent launching decision have come at just the right time.
Get The News You Want
Industry Prospects
Per a report by Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.